Biopharmaceutical company Hoth Therapeutics, Inc., which is focused on unique targeted therapeutics for patients suffering from conditions such as atopic dermatitis, has entered into a sponsored research agreement with the George Washington University (GW) to explore the use of Aprepitant for topical and/or systemic therapy to counter the dermatological related side-effects of Erlotinib therapy in cancer patients.
Erlotinib is a drug that is used to combat various cancers and has been known to cause varying degrees of skin rashes, lesions, hair loss, and nail changes in patients.
The side effects can impact a patient’s quality of life and even cause treatment interruption, jeopardizing the overall success of the therapy.
The research agreement intends to explore whether other chronic conditions that also display dermatitis may benefit from this novel therapeutic approach. Overseeing the collaboration is William B. Weglicki, MD, professor of biochemistry and molecular medicine and professor of medicine at the GW School of Medicine and Health Sciences.
